High expression of UBE2T predicts poor prognosis and survival in multiple myeloma

• DOI: 10.1038/s41417-018-0070-x
• Publication Date: 2019-01-07T22:46:48Z
• Authors: Weilong Zhang; Ye Zhang; Zuozhen Yang; Xiaoni Liu; Ping Yang; Jing Wang; Kai Hu; Xue He; Xiuru Zhang; Hongmei Jing
• Keywords: 0301 basic medicine; Gene Expression; Prognosis; Survival Analysis; Article; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; Recurrence; Cell Line, Tumor; Ubiquitin-Conjugating Enzymes; Biomarkers, Tumor; Humans; Multiple Myeloma; Neoplasm Staging

Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-related substrates, contributing to DNA repair in the Fanconi anemia pathway. Also, numerous evidences reported that UBE2T is closely related to cell proliferation and carcinogenesis. However, the relationship between MM and UBE2T has not been studied. Here, we integrated eight datasets and analyzed the relationship of expression of UBE2T and ISS, 1q21, relapse and survival in MM 2684 patients (totally 2893 samples). We found that the expression of UBE2T increased with the deterioration of MM (P = 1.4e-07), especially in the early stage. UBE2T is closely related to IgG serotype MM (P = 6.9e-05). High expression of UBE2T is associated with poor survival and prognosis (EFS: P = 1.43e-03, OS: P = 5.47e-05). UBE2T is likely to play a part in the cell division pathway, affecting the survival and prognosis of MM. Therefore, UBE2T could be considered as an early alternative biomarker for the prognosis of MM.